Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study. - De Falco V; Colloca A; Argenziano G; Scala M; Guida M; Ottaviano M; Sergi MC; Santarpia M; Del Giudice T; Grimaldi AM; Cozzolino S; Forte M; et al. (Cancer immunology, immunotherapy : CII, 2026)